$LLY news
The latest LLY stock news: headlines, filings, AI summaries and sentiment for $LLY, updated around the clock.
- Ascendis Pharma Reports Q3 Revenue Growth of 90.7% Year-over-Year
- China Approves Eli Lilly's Oral GLP-1 Weight-Loss Drug Orforglipron
- Eli Lilly Raises Revenue Forecast Amid Strong Zepbound Sales and Competition from Viking Therapeutics
- Former Eli Lilly Sales Representative Files Lawsuit Over Alleged Wrongful Termination
- Hims & Hers Reports Q3 2026 Revenue Growth Amid Strategic Marketing Pullback
- FDA Mandates Safety Warnings for GLP-1 Drugs Over Potential Vision Loss Risk
- FDA Requires Vision Loss Warning Label for GLP-1 Weight-Loss Drugs
- US Markets Recover from Post-Election Slump Amid Positive Clinical Trial Data for Eli Lilly and Johnson & Johnson
- Eli Lilly's Oral GLP-1 Foundayo Shows Significant Improvement in Sleep Apnea Phase 3 Trial
- Eli Lilly's Foundayo Obesity Pill Shows Significant Reduction in Sleep Apnea Severity
- Novonesis Explores Microbiome Supplements to Complement GLP-1 Weight-Loss Treatments
- Amgen Develops Monthly Obesity Drug MariTide to Challenge Weekly Injection Market
- Market Volatility Increases Following Midterm Elections as Tech Stocks Face Correction
- Eli Lilly Demonstrates Revenue Growth Beyond GLP-1 Weight Loss Drugs
- Market Outlook: Strong Jobs Data, Tech Volatility, and Key Earnings Results
- Novo Nordisk CEO Provides Timeline for CagriSema Obesity Drug Launch
- Cardinal Health Exceeds Q1 Fiscal 2027 Expectations and Raises Full-Year Guidance
- U.S. Markets Anticipate Treasury Refunding Details Amid Mixed Futures and Strong Corporate Earnings
- Novo Nordisk Raises Full-Year Outlook Following Strong Wegovy Sales
- Eli Lilly Shares Surge Toward Record Highs on Strong GLP-1 Drug Demand
- Eli Lilly Reports 39% Revenue Growth Driven by GLP-1 Drugs Amid High Valuation
- Eli Lilly Reports Strong Third Quarter Results Driven by GLP-1 Growth and Raises Full-Year Guidance
- DPR Construction Appoints Scott Sass as Raleigh-Durham Business Unit Leader
- UBS Initiates Coverage on Viking Therapeutics with Buy Rating and $94 Price Target
- Ark Invest Shifts Focus to Aerospace and Defense While Trimming Semiconductor Holdings
- Weekly Healthcare Market Update: Focus on Eli Lilly, Merck, and AstraZeneca Amid Broad Market Decline
- OmniAb Reports Q3 2026 Revenue Growth and Raises Full-Year Guidance
- Eli Lilly Projects 2026 Revenue Between $91B and $92B Amid GLP-1 Expansion
- Eli Lilly Reports Strong Q3 2026 Results Driven by Mounjaro and Zepbound Demand
- Eli Lilly Reports 39% Revenue Growth Driven by Increased Sales Volume
- West Pharmaceutical Services Exceeds Earnings Expectations and Raises Full-Year Guidance
- Eli Lilly Raises Price Target Amid Strong Third Quarter Earnings and Obesity Drug Growth
- Jim Cramer Analyzes Tech Selloff and Highlights Gains for Eli Lilly and FedEx
- ELI LILLY & Co - 10-Q Filing
- Pomerantz Law Firm Investigates Foghorn Therapeutics Following Clinical Program Termination and Workforce Reduction
- Market Analysis: Tech Volatility and Mixed Earnings Impacting Major Stocks
- Eli Lilly Reports Strong Q3 Results Driven by Mounjaro and Jardiance Growth
- Alexandria Real Estate Equities Celebrates 20 Years of Prix Galien USA Partnership
- Pre-market Trading Analysis: Alphabet, Microsoft, and Eli Lilly Lead Earnings Volatility
- Eli Lilly Raises Full-Year Revenue Outlook Driven by Strong Weight-Loss Drug Demand
- ELI LILLY & Co - 8-K Filing
- Eli Lilly Set to Report Third-Quarter Earnings Driven by Obesity and Diabetes Drugs
- Nasdaq-100 Futures Decline Following Alphabet Earnings Miss Amid Mixed Hyperscaler Results
- Major Corporate Earnings Reports Scheduled Before Market Open on Thursday
- Jim Cramer Identifies Buying Opportunities in Boeing and GE Vernova Amid Market Uncertainty
- Merck and Eli Lilly Prepare for Third-Quarter Earnings Reports
- Eli Lilly's Retatrutide Demonstrates Superior Weight Loss and A1C Reduction Compared to Ozempic in Phase 3 Trial
- Eli Lilly to Consolidate US and International Units into Lilly Global Markets by 2027
- US Judge Denies Novo Nordisk Request to Halt Eli Lilly Weight-Loss Drug Advertisements
- Eli Lilly Announces Quarterly Dividend of $1.73 Per Share